Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Breaks a Biotech Taboo: The Hostile Bid For AnorMED

Executive Summary

In late August, Genzyme launched a hostile bid for AnorMED, a Canadian biotech with an unpartnered stem cell mobilizer called MOZOBIL currently in Phase III clinical trials. When Millennium Pharmaceuticals Inc. jumped in with a higher offer, it set off a bidding war that has been dubbed "The battle of Boston". Ultimately, Genzyme prevailed, but in deciding to go directly to AnorMED's shareholders with its bid, that company's management broke one of the last taboos of biotech M&A. The move illustrates business development execs' desperate need to nab suitable assets that might help cure pipeline woes. Indeed, it appears unencumbered late stage assets are now so rare that their value may exceed estimates ascribed by the market; and this is true even if the people working on that asset are lost, as typically occurs following unsolicited offers.
Advertisement
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002679

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel